Search research articles
Contact Us
Filters
Showing results (91-100 of 104) with videos related to
Page
of 11
Sort By:
Molecular Oncology
|
February 15, 2024
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling
Carlos Marugán, Natalia Sanz-Gómez, Beatriz Ortigosa, et al.
Oncotarget
|
October 21, 2017
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Raquel Torres-Guzmán, Bruna Calsina, Ana Hermoso, et al.
Frontiers in Oncology
|
April 15, 2025
Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcoma<i>-</i>mutation gene expression subtype: retrospective analysis from the JUNIPER Trial
Jiangang Liu, Hong Wang, Amit Aggarwal, et al.
Oncotarget
|
May 12, 2020
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
Lacey M Litchfield, Karsten Boehnke, Manisha Brahmachary, et al.
Investigational New Drugs
|
June 13, 2014
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M Gelbert, Shufen Cai, Xi Lin, et al.
Bioorganic & Medicinal Chemistry
|
January 17, 2024
Design, synthesis and validation of a new Crimped Head-Piece for DNA-Encoded libraries generation
Ramón Rama-Garda, María Dolores Martin-Ortega, Anthony de Jesús Sánchez, et al.
NPJ Breast Cancer
|
December 28, 2022
Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
Severine Isabelle Gharbi, Laura A Pelletier, Alfonso Espada, et al.
NPJ Breast Cancer
|
November 29, 2022
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
Severine Isabelle Gharbi, Laura A Pelletier, Alfonso Espada, et al.
Oncotarget
|
February 23, 2018
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
Jonathan M Yingling, William T McMillen, Lei Yan, et al.
Molecular Cancer Therapeutics
|
April 2, 2014
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models
Tinggui Yin, Maria J Lallena, Emiko L Kreklau, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 104) with videos related to
Sort By:
Page
of 11
Molecular Oncology
|
February 15, 2024
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling
Carlos Marugán, Natalia Sanz-Gómez, Beatriz Ortigosa, et al.
Oncotarget
|
October 21, 2017
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Raquel Torres-Guzmán, Bruna Calsina, Ana Hermoso, et al.
Frontiers in Oncology
|
April 15, 2025
Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcoma<i>-</i>mutation gene expression subtype: retrospective analysis from the JUNIPER Trial
Jiangang Liu, Hong Wang, Amit Aggarwal, et al.
Oncotarget
|
May 12, 2020
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
Lacey M Litchfield, Karsten Boehnke, Manisha Brahmachary, et al.
Investigational New Drugs
|
June 13, 2014
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M Gelbert, Shufen Cai, Xi Lin, et al.
Bioorganic & Medicinal Chemistry
|
January 17, 2024
Design, synthesis and validation of a new Crimped Head-Piece for DNA-Encoded libraries generation
Ramón Rama-Garda, María Dolores Martin-Ortega, Anthony de Jesús Sánchez, et al.
NPJ Breast Cancer
|
December 28, 2022
Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
Severine Isabelle Gharbi, Laura A Pelletier, Alfonso Espada, et al.
NPJ Breast Cancer
|
November 29, 2022
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
Severine Isabelle Gharbi, Laura A Pelletier, Alfonso Espada, et al.
Oncotarget
|
February 23, 2018
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
Jonathan M Yingling, William T McMillen, Lei Yan, et al.
Molecular Cancer Therapeutics
|
April 2, 2014
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models
Tinggui Yin, Maria J Lallena, Emiko L Kreklau, et al.
Page
of 11